Originally developed for type 2 diabetes management, tirzepatide gained FDA approval for weight loss under the brand name Zepbound in 2023 after clinical trials demonstrated superior weight loss compared to semaglutide and other GLP-1 medications
Its an exciting time for personalized medicine, and I think WHIM is going to be a poster child for rare diseases and the ability where were at now in modern medicine to design therapies to treat underlying genetic disorders, Teresa Tarrant, an associate professor at Duke Universitys School of Medicine and lead investigator of the 4WHIM trial, told BioSpace prior to Xolremdis approval
It should not be injected into the muscle or vein
A deeper understanding of the dynamic continuum linking metabolism, body composition, systemic inflammation, and immune regulation may enable more precise patient stratification and open opportunities for personalized immunotherapy strategies
Effective January 1, 2024, Health New England has expanded our HDHP drug benefit making select preventative drugs more affordable